Form 4: Artiva Biotherapeutics CEO Aslan Swaps Options for RSUs

Artiva Biotherapeutics' President and CEO, Fred Aslan, exchanged employee stock options for 869,136 restricted stock units on December 12, 2025.

Summary

• Fred Aslan, President and CEO of Artiva Biotherapeutics, Inc. (ARTV), reported an option exchange transaction on December 12, 2025.
• Aslan acquired 869,136 shares of Common Stock in the form of Restricted Stock Units (RSUs) at an acquisition price of $0 per share, granted under the Issuer's 2024 Equity Incentive Plan.
• Concurrently, he disposed of 869,136 employee stock options with various exercise prices ranging from $5.01 to $13.47, which were cancelled as part of the option exchange.
• Following this transaction, Aslan directly beneficially owns 1,213,135 shares of Common Stock and holds no derivative securities.
• The vesting schedules for the cancelled options varied, with some shares having vested as early as February 2022 and others scheduled to vest through July 2025 and beyond.

Sentiment

Score: 6

Explanation: The transaction is a routine executive compensation adjustment, converting options to RSUs, which is generally neutral but can be seen as slightly positive for long-term incentive alignment.

Positives

• The transaction consolidates a significant portion of the CEO's equity holdings into direct stock ownership (RSUs), potentially aligning his interests more closely with long-term shareholder value.
• The acquisition of 869,136 RSUs at a $0 price represents a substantial equity grant, increasing the CEO's direct stake in the company's future performance.

Negatives

• The cancellation of existing employee stock options, some with exercise prices up to $13.47, and their replacement with RSUs, represents a change in the CEO's equity incentive structure. This could be interpreted as a reset of incentives, potentially at a lower effective cost basis for the new RSUs compared to the original options if the stock price has declined, though the filing does not explicitly state the reason for the exchange.

Risks

• The value of the newly acquired Restricted Stock Units (RSUs) is directly tied to the future market performance of Artiva Biotherapeutics' common stock, exposing the CEO's compensation to market volatility.
• The vesting schedules for the RSUs extend over several years, meaning the full benefit of the grant is contingent on the company's long-term performance and the CEO's continued employment.

Future Outlook

The transaction reflects a strategic adjustment in executive equity compensation, aligning the CEO's incentives with the long-term performance of Artiva Biotherapeutics through Restricted Stock Units, which typically vest over several years.

Industry Context

Option exchanges and RSU grants are common practices in the biotechnology and pharmaceutical industries, particularly for early-stage or growth companies like Artiva Biotherapeutics, to retain key executives, realign incentives, and manage equity dilution, especially when stock options may be underwater or to provide more direct equity ownership.

Comparison to Industry Standards

• Option exchange programs are a recognized tool in executive compensation, often employed by biotech companies to re-incentivize management when stock prices have underperformed, making existing options less effective.
• The grant of Restricted Stock Units (RSUs) at a $0 acquisition price is a standard form of equity compensation, similar to practices at peer companies such as CRISPR Therapeutics (CRSP) or Editas Medicine (EDIT), where RSUs are used to provide direct equity ownership and long-term retention incentives.
• Vesting schedules, such as the 36-month or 48-month periods mentioned, are typical for executive equity awards in the biotech sector, designed to ensure long-term commitment and align executive interests with shareholder value creation over several years.

Stakeholder Impact

• Shareholders: The option exchange and RSU grant could be viewed as a re-alignment of executive incentives, potentially leading to better long-term performance if the new structure is more motivating. However, the grant of RSUs at $0 effectively increases the number of shares outstanding upon vesting, which could lead to future dilution.
• Employees: The transaction specifically relates to the CEO's compensation and does not directly impact other employees, though it sets a precedent for executive incentive structures.

Next Steps

• Continued vesting of the 869,136 Restricted Stock Units according to their respective schedules.
• Fred Aslan will continue to file Forms 3, 4, and 5 as required by Section 16(a) of the Securities Exchange Act of 1934.

Key Dates

Recommendation

This Form 4 reports a routine executive compensation adjustment where the CEO exchanged existing stock options for Restricted Stock Units. Such transactions are common for incentive alignment and do not typically signal a fundamental change in the company's prospects or warrant a change in investment recommendation based solely on this filing. Investors should continue to monitor the company's operational performance and broader market trends.

Keywords

Artiva Biotherapeutics, ARTV, Fred Aslan, SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Equity Incentive Plan, Executive Compensation, Option Exchange